查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1546243

现实世界证据解决方案的全球市场

Real World Evidence Solutions
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 246 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球真实证据解决方案市场预计将达到 44 亿美元

现实世界证据解决方案的全球市场预计 2023 年为 17 亿美元，预计到 2030 年将达到 44 亿美元，2023 年至 2030 年复合年增长率为 14.3%。真实世界证据服务是本报告分析的细分市场之一，预计复合年增长率为 15.5%，到分析期结束时将达到 29 亿美元。在分析期间，现实世界证据资料集领域的复合年增长率预计为 12.1%。

美国市场预估为4.609亿美元，中国预期复合年增长率为13.3%

到 2023 年，美国现实世界证据解决方案市场预计将达到 4.609 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达6.526亿美元，2023-2030年分析期间复合年增长率为13.3%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间复合年增长率分别为 12.9% 和 12.0%。在欧洲，德国预计复合年增长率为 10.1%。

全球真实世界证据解决方案市场 - 主要趋势与驱动因素摘要

真实世界证据解决方案：透过资料驱动的见解改变医疗保健

真实世界证据 (RWE) 解决方案正在透过提供资料主导的见解来改变医疗保健，从而增强跨行业的决策。 RWE 是透过真实世界资料(RWD) 分析得出的有关药物使用以及潜在益处或风险的临床证据。这些资料是从各种资讯来源收集的，包括电子健康记录(EHR)、申请资料库、病患登记和穿戴式装置。 RWE 越来越多地被製药公司、监管机构和医疗保健提供者用来为药物开发、监管核准和患者护理策略提供资讯。与在受控条件下进行的传统临床试验不同，RWE 可以深入了解治疗在常规临床实践中的表现，从而更全面地了解产品的功效和安全性。这种方法对于展示新治疗方法的价值至关重要，特别是在个人化医疗和罕见疾病方面。

哪些技术进步正在增强 RWE 的收集和利用？

技术进步极大地增强了 RWE 的收集、分析和利用，使其成为医疗保健利益相关人员更强大的工具。透过将巨量资料分析、人工智慧 (AI) 和机器学习 (ML) 整合到 RWE 平台中，我们可以处理大量 RWD 并发现无法手动检测的模式和见解。资料整合技术的进步还可以集中来自不同来源的资料，创建全面的资料集，提供患者结果的整体视图。此外，自然语言处理 (NLP) 的使用正在改善从医生笔记和社交媒体等非结构化来源中提取有意义的资料。这些创新不仅提高了 RWE 的品质和准确性，而且使医疗保健决策者更容易获得和实用。

RWE 在医疗保健领域的主要用途和好处是什么？

RWE 在医疗保健领域有着广泛的应用，在改善病患治疗效果、提高医疗效率和支持监管决策方面具有显着优势。在药物开发中，RWE 用于补充临床试验资料，深入了解药物在不同人群和现实环境中的表现，并为标籤和上市后监测提供资讯。医疗保健提供者使用 RWE 来确定针对特定患者群体的最有效的治疗方法，以支援根据个人需求量身定制治疗的个人化医疗方法。付款人和保险公司利用 RWE 来评估治疗的成本效益、指导报销决策并确保将资源分配给提供最大价值的治疗。 RWE 的主要好处包括透过深入了解医疗产品的真实有效性和安全性来治疗患者、支持以证据为基础的决策以及根据真实患者体验告知治疗策略，其中包括改进的能力。

推动现实世界证据解决方案市场成长的因素有哪些？

现实世界证据解决方案市场的成长受到多种因素的推动。随着医疗保健相关人员寻求基于确凿证据做出明智决策，对基于价值的医学的日益重视以及证明医疗产品在现实世界中的有效性的需求是一个主要的驱动因素。资料分析、人工智慧和数位健康平台的技术进步也透过增加 RWE 解决方案的功能和可访问性来推动市场成长。对个人化医疗的需求不断增长，以及支援监管核准的资料需求，特别是对于罕见和复杂的疾病，进一步推动了对 RWE 的需求。此外，电子病历、穿戴式装置和病患报告结果的采用正在增加数位健康资料的可用性，扩大 RWE 调查的范围和规模。这些因素，加上製药公司、医疗保健提供者和监管机构之间日益加强的合作，正在推动现实世界证据解决方案市场的持续成长。

受访的公司范例（所有 46 家有兴趣的公司）

  • Aetion
  • Cognizant Technology Solutions US Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP14362

Global Real World Evidence Solutions Market to Reach US$4.4 Billion by 2030

The global market for Real World Evidence Solutions estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2023-2030. Real World Evidence Services, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Real World Evidence Data Sets segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$460.9 Million While China is Forecast to Grow at 13.3% CAGR

The Real World Evidence Solutions market in the U.S. is estimated at US$460.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$652.6 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Real World Evidence Solutions Market - Key Trends and Drivers Summarized

Real World Evidence Solutions: Transforming Healthcare with Data-Driven Insights

Real World Evidence (RWE) solutions are transforming healthcare by providing data-driven insights that enhance decision-making across the industry. RWE refers to the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD). This data is collected from various sources, including electronic health records (EHRs), claims databases, patient registries, and wearable devices. RWE is increasingly being used by pharmaceutical companies, regulators, and healthcare providers to inform drug development, regulatory approvals, and patient care strategies. Unlike traditional clinical trials, which are conducted under controlled conditions, RWE provides insights into how treatments perform in everyday clinical settings, offering a more comprehensive understanding of a product’s effectiveness and safety. This approach is becoming essential for demonstrating the value of new therapies, especially in personalized medicine and for rare diseases.

What Technological Advancements Are Enhancing the Collection and Utilization of RWE?

Technological advancements are significantly enhancing the collection, analysis, and utilization of RWE, making it a more powerful tool for healthcare stakeholders. The integration of big data analytics, artificial intelligence (AI), and machine learning (ML) into RWE platforms allows for the processing of vast amounts of RWD, uncovering patterns and insights that would be impossible to detect manually. Advances in data integration technologies are also enabling the aggregation of data from diverse sources, creating comprehensive datasets that provide a holistic view of patient outcomes. Moreover, the use of natural language processing (NLP) is improving the extraction of meaningful data from unstructured sources, such as physician notes and social media. These technological innovations are not only improving the quality and accuracy of RWE but are also making it more accessible and actionable for decision-makers in healthcare.

What Are the Key Applications and Benefits of RWE in Healthcare?

RWE is used in a wide range of applications in healthcare, offering significant benefits that enhance patient outcomes, improve healthcare efficiency, and support regulatory decision-making. In drug development, RWE is used to supplement clinical trial data, providing insights into how a drug performs across different populations and in real-world settings, which can inform labeling and post-market surveillance. Healthcare providers use RWE to identify the most effective treatments for specific patient populations, supporting personalized medicine approaches that tailor care to individual needs. Payers and insurers leverage RWE to assess the cost-effectiveness of treatments, guiding reimbursement decisions and ensuring that resources are allocated to therapies that offer the greatest value. The primary benefits of RWE include its ability to provide insights into the real-world effectiveness and safety of medical products, support evidence-based decision-making, and improve patient care by informing treatment strategies based on actual patient experiences.

What Factors Are Driving the Growth in the Real World Evidence Solutions Market?

The growth in the Real World Evidence Solutions market is driven by several factors. The increasing emphasis on value-based care and the need to demonstrate the real-world effectiveness of medical products are significant drivers, as healthcare stakeholders seek to make informed decisions based on robust evidence. Technological advancements in data analytics, AI, and digital health platforms are also propelling market growth by enhancing the capabilities and accessibility of RWE solutions. The rising demand for personalized medicine and the need for data to support regulatory approvals, particularly for rare diseases and complex conditions, are further boosting demand for RWE. Additionally, the growing availability of digital health data, driven by the adoption of EHRs, wearable devices, and patient-reported outcomes, is expanding the scope and scale of RWE studies. These factors, combined with increasing collaboration between pharmaceutical companies, healthcare providers, and regulatory bodies, are driving the sustained growth of the Real World Evidence Solutions market.

Select Competitors (Total 46 Featured) -

  • Aetion
  • Cognizant Technology Solutions U.S. Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Real World Evidence Solutions - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Evidence-Based Healthcare Propels Market Growth
    • Technological Advancements in Data Integration and Analytics Strengthen Market Position
    • Growing Focus on Personalized Medicine and Patient-Centric Care Drives Adoption of Real World Evidence Solutions
    • Surge in Demand for Post-Market Surveillance and Safety Monitoring Generates New Opportunities
    • Development of Advanced Data Collection and Management Platforms Sustains Market Growth
    • Expanding Applications in Drug Development and Clinical Trials Throws Spotlight on Market Potential
    • Rising Adoption of Real World Evidence in Payer Decision-Making and Reimbursement Processes Propels Market Expansion
    • Surge in Demand for Real-Time Data and Predictive Analytics Expands Market Horizons
    • Growing Awareness of the Benefits of Real World Evidence in Enhancing Treatment Outcomes Drives Market Adoption
    • Innovations in Artificial Intelligence and Machine Learning Generate New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Data Sets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Data Sets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Real World Evidence Solutions Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Devices Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Pharmaceutical & Medical Devices Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 16: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: USA 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 18: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Japan 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 28: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: China 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 30: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 40: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Germany 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Italy 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 52: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of World 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION